Sanofi wins US approval for multiple myeloma drug in newly …
WEB1 day ago · Sanofi won approval for the use of a drug combination with its Sarclisa infusion to treat certain types of newly diagnosed multiple myeloma, where it has previously been used only after...
Press Room - Sanofi US News
WEB2 days ago · Advancing SARCLISA in multiple myeloma. Sanofi continues to advance SARCLISA as part of a patient-centric clinical development program, which includes several phase 2 and phase 3 studies across the MM treatment …
Sanofi moves on J&J in first-line myeloma with FDA nod
WEB1 day ago · ASH: J&J, Sanofi square off in newly diagnosed multiple myeloma, with one med showing 'unprecedented' efficacy. Meanwhile, J&J has been switching patients to a subcutaneous formulation of...
Press Release: Sarclisa approved in the US as the first anti-CD38 ...
WEB1 day ago · Sanofi - Aventis Groupe. Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not...
Press Room - Sanofi US News
WEBAug 8, 2024 · GMMG-HD7 is one of six phase 3 studies to report positive results for Sarclisa in multiple myeloma (MM), which includes four positive readouts of a Sarclisa-based quadruplet in the frontline setting. Results reinforce the potential of Sarclisa as a backbone therapy when added to the current standard-of-care in …
Sanofi US News
WEBJun 3, 2024 · Sarclisa is a monoclonal antibody that binds to a specific epitope on the CD38 receptor on multiple myeloma (MM) cells, inducing distinct antitumor activity. It is designed to work through multiple mechanisms of action including programmed tumor cell death (apoptosis) and immunomodulatory activity.
Press Release: Sarclisa accepted for FDA priority review for ... - Sanofi
WEBMay 27, 2005 · If approved, Sarclisa would be the first anti-CD38 therapy in combination with standard-of-care treatment for patients with newly diagnosed transplant-ineligible multiple myeloma. Pivotal IMROZ phase 3 study results to be featured during oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Paris, May 27 ...
Press Release: Sarclisa induction treatment demonstrated ... - Sanofi
WEBAug 8, 2005 · New results from the two-part, double-randomized, German-speaking Myeloma Multicenter Group (GMMG)-HD7 phase 3 study show that Sarclisa (isatuximab) in combination with lenalidomide, bortezomib, and dexamethasone (RVd) during induction therapy in transplant-eligible, newly diagnosed multiple myeloma (NDMM) significantly prolonged progression ...
FDA Approves Sarclisa with VRd | Int'l Myeloma Foundation
WEB2 days ago · According to a September 20, 2024, press release, the U.S. Food and Drug Administration (FDA) has "approved isatuximab-irfc (Sarclisa, Sanofi-Aventis U.S. LLC) with bortezomib, lenalidomide, and dexamethasone for adults with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant (ASCT)."
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple …
WEBJun 3, 2024 · In an international, open-label, phase 3 trial, we randomly assigned, in a 3:2 ratio, patients 18 to 80 years of age with newly diagnosed multiple myeloma who were ineligible to undergo...